Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Adaptimmune logo — Designing and delivering cell therapies to transform the liv...

Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.

Founded 2008 United Kingdom Abingdon, United Kingdom 200 employees Post-IPO Debt Total: $499.50M Biopharma, Biotechnology +1

General Information

Company Name Adaptimmune
Founded Year 2008
Location United Kingdom Abingdon, United Kingdom
Founders / Decision Makers
Team member Team member
Employees 200
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Debt
Business Model B2B, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Adaptimmune. To contact Adaptimmune, visit adaptimmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Adaptimmune compare?

A PDF of Adaptimmune and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Adaptimmune soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Adaptimmune

Adaptimmune stands as a pioneering entity in the biopharmaceutical landscape, specializing in cell therapies designed to revolutionize cancer treatment. With its strong presence in four biotechnology hubs across the U.K. and U.S., the company showcases comprehensive competencies ranging from preclinical research to commercial operations.

Founded in 2008, Adaptimmune has established itself as a significant player in the Biopharma, Biotechnology, and Health Care sectors. The recent financial endorsement came as a $25.00M Post-IPO Debt investment on May 15, 2024, led by Hercules Capital, underscoring investor confidence in their innovative capabilities.

As Adaptimmune advances its groundbreaking cell therapy solutions, it remains an attractive prospect for venture capitalists interested in companies with strong growth potential and transformative technologies in oncology.

Business keywords: Cell Therapy, Cancer Treatment, T Cell Therapies, Preclinical Research, Clinical Development, Translational Sciences, Autologous Manufacturing, Allogeneic Manufacturing, T Cell Receptor Proteins, Affinity T Cell Receptor, Immunotherapy, Infectious Disease Treatment, HIV Therapy, Corporate Operations

Services & Products

Development of T-cell therapies
Pipeline management of cell therapies
Sale and licensing of cell therapies
Biotechnological research
Clinical trials

Target Customers

Cancer patients Healthcare professionals Biopharmaceutical companies Medical researchers

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $25.00M 1
Hercules Capital
Hercules Capital
15 May 2024
Post IPO Equity $150.00M 1
Genentech
07 Sep 2021
Post IPO Equity $75.00M -
30 Aug 2019
Post IPO Equity $100.00M -
06 Sep 2018
Post IPO Equity $42.00M -
11 Apr 2017
Venture Round Undisclosed 1
Eight Roads Ventures
Eight Roads Ventures
04 Feb 2015
Series A $104.00M 10
New Enterprise Associates Novo Holdings OrbiMed
New Enterprise Associates, Novo Holdings +8
25 Sep 2014
Grant $3.50M 1
Biomedical Catalyst Fund
26 Mar 2014
Venture Round Undisclosed 1
Sahsen Ventures
Sahsen Ventures
01 Jan 2014

Adaptimmune Alternatives & Competitors

View All Alternatives
Adaptimmune vs
Legend Biotech
Legend Biotech United States

Multinational biopharmaceutical company focused on discovering and developing cutting-edge cell-base...

2565 employees
Biotechnology, Health Care
Compare Adaptimmune vs Legend Biotech
Adaptimmune vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Compare Adaptimmune vs Adicet Bio, Inc
Adaptimmune vs
Autolus Therapeutics
Autolus Therapeutics United Kingdom

Focused on the development of precisely targeted, controlled & highly active T cell therapies for ca...

Post-IPO Equity
720 employees
Biopharma, Biotechnology
Compare Adaptimmune vs Autolus Therapeutics
View all alternatives

FAQ About Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.
Adaptimmune was founded in 2008.
Adaptimmune is headquartered in Abingdon, United Kingdom.
Adaptimmune operates in Biopharma, Biotechnology and Health Care. Its work centres on Cell Therapy, Cancer Treatment, T Cell Therapies and Preclinical Research. Its customers include Cancer patients, Healthcare professionals and Biopharmaceutical companies.
Adaptimmune has a B2B and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Adaptimmune has approximately 200 employees.
Adaptimmune has completed 9 funding rounds, raising a total of $499.50M. The latest funding stage is Post-IPO Debt.
Adaptimmune offers: Development of T-cell therapies, Pipeline management of cell therapies, Sale and licensing of cell therapies, Biotechnological research, Clinical trials.
Top alternatives and competitors to Adaptimmune include Legend Biotech, Adicet Bio, Inc, Autolus Therapeutics, Kite Pharma, Avenzo Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adaptimmune and Legend Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Adaptimmune, https://bouncewatch.com/company/adaptimmune, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes